Structure-activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist.

[1]  G. Schmalzing,et al.  NF449, a novel picomolar potency antagonist at human P2X1 receptors. , 2003, European journal of pharmacology.

[2]  T. Brennan,et al.  A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[3]  C. Müller.  P2-pyrimidinergic receptors and their ligands. , 2002, Current pharmaceutical design.

[4]  M. Kassack,et al.  Structure-activity relationships of suramin and pyridoxal-5'-phosphate derivatives as P2 receptor antagonists. , 2002, Current pharmaceutical design.

[5]  K. Jacobson,et al.  Purine and pyrimidine (P2) receptors as drug targets. , 2002, Journal of medicinal chemistry.

[6]  J. Lehmann,et al.  Functional Screening of G Protein—Coupled Receptors by Measuring Intracellular Calcium with a Fluorescence Microplate Reader , 2002, Journal of biomolecular screening.

[7]  J. Debus,et al.  Detection and quantification of the soluble form of the human erythropoietin receptor (sEpoR) in the growth medium of tumor cell lines and in the plasma of blood samples , 2002, Clinical and Experimental Medicine.

[8]  M. Parmentier,et al.  Identification of a Novel Human ADP Receptor Coupled to Gi * , 2001, The Journal of Biological Chemistry.

[9]  G. Schmalzing,et al.  NF449: a subnanomolar potency antagonist at recombinant rat P2X1 receptors , 2001, Naunyn-Schmiedeberg's Archives of Pharmacology.

[10]  B S Khakh,et al.  International union of pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits. , 2001, Pharmacological reviews.

[11]  F. Di Virgilio,et al.  Nucleotide receptors: an emerging family of regulatory molecules in blood cells. , 2001, Blood.

[12]  G. Schmalzing,et al.  The suramin analogue NF279 is a novel and potent antagonist selective for the P2X1 receptor , 2000, Neuropharmacology.

[13]  A. Wetter,et al.  Molecular pharmacology of P2Y-receptors , 2000, Naunyn-Schmiedeberg's Archives of Pharmacology.

[14]  G. Lambrecht.  Agonists and antagonists acting at P2X receptors: selectivity profiles and functional implications , 2000, Naunyn-Schmiedeberg's Archives of Pharmacology.

[15]  H. Bäumert,et al.  The novel heteromeric bivalent ligand SB9 potently antagonizes P2Y(1) receptor-mediated responses. , 2000, Journal of the autonomic nervous system.

[16]  J. Chambers,et al.  A G Protein-coupled Receptor for UDP-glucose* , 2000, The Journal of Biological Chemistry.

[17]  G. Schmalzing,et al.  The novel pyridoxal-5'-phosphate derivative PPNDS potently antagonizes activation of P2X(1) receptors. , 2000, European journal of pharmacology.

[18]  J. Boeynaems,et al.  Pharmacological characterization of the human P2Y11 receptor , 1999, British journal of pharmacology.

[19]  W. Stühmer,et al.  Antagonistic properties of the suramin analogue NF023 at heterologously expressed P2X receptors , 1999, Neuropharmacology.

[20]  G Burnstock,et al.  Receptors for purines and pyrimidines. , 1998, Pharmacological reviews.

[21]  G. Schmalzing,et al.  NF279: a novel potent and selective antagonist of P2X receptor-mediated responses. , 1998, European journal of pharmacology.

[22]  M. Kassack,et al.  Sulfanilic Acid‐, Benzenedisulfonic Acid‐, and Naphthalenetrisulfonic Acid Analogues , 1998, Archiv der Pharmazie.

[23]  W. Stühmer,et al.  Cloned Ligand-gated Channels Activated by Extracellular ATP (P2X Receptors) , 1997, The Journal of Membrane Biology.

[24]  R. Nicholas,et al.  HEK293 human embryonic kidney cells endogenously express the P2Y1 and P2Y2 receptors , 1997, Neuropharmacology.

[25]  G. Burnstock,et al.  Vasoconstrictor responses via P2X‐receptors are selectively antagonized by NF023 in rabbit isolated aorta and saphenous artery , 1997, British journal of pharmacology.

[26]  M. Kassack,et al.  Rapid, highly sensitive gradient narrow-bore high-performance liquid chromatographic determination of suramin and its analogues. , 1996, Journal of chromatography. B, Biomedical applications.

[27]  K. Starke,et al.  P2-purinoceptor antagonists: III. Blockade of P2-purinoceptor subtypes and ecto-nucleotidases by compounds related to suramin , 1996, Naunyn-Schmiedeberg's Archives of Pharmacology.

[28]  P. Humphrey,et al.  Evidence for the presence of two types of P2 purinoceptor in the guinea-pig ileal longitudinal smooth muscle preparation. , 1994, European journal of pharmacology.

[29]  H. Bäumert,et al.  PPADS, a novel functionally selective antagonist of P2 purinoceptor-mediated responses. , 1992, European journal of pharmacology.

[30]  A. Blakeley,et al.  Suramin: a reversible P2‐purinoceptor antagonist in the mouse vas deferens , 1988, British journal of pharmacology.

[31]  P. Nickel,et al.  [Potential filaricides. Suramin analogs]. , 1986, Arzneimittel-Forschung.

[32]  D. Seyferth.  Houben-Weyl methoden der organischen chemie , 1978 .

[33]  G Burnstock,et al.  Potential therapeutic targets in the rapidly expanding field of purinergic signalling. , 2002, Clinical medicine.

[34]  R. North,et al.  Pharmacology of cloned P2X receptors. , 2000, Annual review of pharmacology and toxicology.

[35]  G. Schmalzing,et al.  Novel ligands for P2 receptor subtypes in innervated tissues. , 1999, Progress in brain research.

[36]  G. Burnstock,et al.  Purinoceptors: are there families of P2X and P2Y purinoceptors? , 1994, Pharmacology & therapeutics.